51 related articles for article (PubMed ID: 19806450)
1. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors.
Dajti G; Serra M; Cisternino G; Ceccarelli C; Pellegrini A; Melina M; De Leo A; Santini D; Taffurelli M; Zanotti S
Oncologist; 2024 May; 29(5):384-391. PubMed ID: 37995311
[TBL] [Abstract][Full Text] [Related]
3. Invasion and Metastasis as a Central Hallmark of Breast Cancer.
Saha T; Solomon J; Samson AO; Gil-Henn H
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441794
[TBL] [Abstract][Full Text] [Related]
4. A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.
Arana Echarri A; Beresford M; Campbell JP; Jones RH; Butler R; Gollob KJ; Brum PC; Thompson D; Turner JE
Front Immunol; 2020; 11():616188. PubMed ID: 33597950
[TBL] [Abstract][Full Text] [Related]
5. Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?
Schmidt G; Solomayer EF; Bohle RM; Gerlinger C; Radosa JC; Endrikat J; Kasoha M
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2109-2116. PubMed ID: 32266539
[TBL] [Abstract][Full Text] [Related]
6. TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.
Shahbandi A; Nguyen HD; Jackson JG
Trends Cancer; 2020 Feb; 6(2):98-110. PubMed ID: 32061310
[TBL] [Abstract][Full Text] [Related]
7. Gene expression association study in feline mammary carcinomas.
Ferreira D; Martins B; Soares M; Correia J; Adega F; Ferreira F; Chaves R
PLoS One; 2019; 14(8):e0221776. PubMed ID: 31461477
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
Abubakar M; Guo C; Koka H; Sung H; Shao N; Guida J; Deng J; Li M; Hu N; Zhou B; Lu N; Yang XR
NPJ Breast Cancer; 2019; 5():20. PubMed ID: 31372496
[No Abstract] [Full Text] [Related]
9. Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.
Pare R; Soon PS; Shah A; Lee CS
PLoS One; 2019; 14(4):e0214604. PubMed ID: 30998679
[TBL] [Abstract][Full Text] [Related]
10. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.
Zou G; Ren B; Liu Y; Fu Y; Chen P; Li X; Luo S; He J; Gao G; Zeng Z; Xiong W; Li G; Huang Y; Xu K; Zhang W
Cancer Sci; 2018 Nov; 109(11):3416-3427. PubMed ID: 30151927
[TBL] [Abstract][Full Text] [Related]
11. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
[TBL] [Abstract][Full Text] [Related]
12. Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma.
Chen H; Li Y; Long Y; Tang E; Wang R; Huang K; Xie C; Chen G
Oncotarget; 2017 Aug; 8(32):53226-53233. PubMed ID: 28881806
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Transverse Relaxation Rate (R2*) in Blood Oxygenation Level-Dependent Magnetic Resonance Imaging in Patients with Invasive Breast Cancer.
Choi HY; Ko ES; Han BK; Kim EJ; Kim SM; Lim Y; Kim RB
PLoS One; 2016; 11(7):e0158500. PubMed ID: 27384310
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.
Lee SK; Bae SY; Lee JH; Lee HC; Yi H; Kil WH; Lee JE; Kim SW; Nam SJ
PLoS One; 2015; 10(8):e0124658. PubMed ID: 26241661
[TBL] [Abstract][Full Text] [Related]
15. A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
Pang B; Sun SP; Gao L; Zhu RL; Zhang LX; An C; Liu ZY; Liu GJ
Med Oncol; 2014 Jul; 31(7):30. PubMed ID: 24908061
[TBL] [Abstract][Full Text] [Related]
16. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
[TBL] [Abstract][Full Text] [Related]
17. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
18. Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
Rezano A; Kuwahara K; Yamamoto-Ibusuki M; Kitabatake M; Moolthiya P; Phimsen S; Suda T; Tone S; Yamamoto Y; Iwase H; Sakaguchi N
BMC Cancer; 2013 Dec; 13():562. PubMed ID: 24289229
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.
Rofaiel S; Muo EN; Mousa SA
Pharmgenomics Pers Med; 2010; 3():129-43. PubMed ID: 23226048
[TBL] [Abstract][Full Text] [Related]
20. Exploring molecular pathways of triple-negative breast cancer.
Ossovskaya V; Wang Y; Budoff A; Xu Q; Lituev A; Potapova O; Vansant G; Monforte J; Daraselia N
Genes Cancer; 2011 Sep; 2(9):870-9. PubMed ID: 22593799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
